65,437 trials
Leukaemia, Lymphoblastic
Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…
Impulse Control Disorder · Parkinson Disease
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on the Clinical Global Impression-Improvement (CGI-I) Scale — 54.4; 33.1 percentage of…
Relapsing Remitting Multiple Sclerosis
Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale
Diabetic Neuropathy, Painful
Primary: Baseline Mean Pain Score — 6.65; 6.67 units on a scale
Myeloma
Primary: Maximum Tolerated Dose (MTD) of Siltuximab — 8.3 mg/kg
Rheumatoid Arthritis
Primary: Percentage of American College of Rheumatology [ACR] 20 Criteria Responders — 69.5; 30.7; NA; 71.3 Percentage of Participants
Low Back Pain · Back Pain
Primary: Change in Back Pain — 6; 8.5; 4; 1.5 units on a scale
Venous Thromboembolism
Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…
Major Depressive Disorder
Primary: Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D) — -8.19; -7.83; -13.6 units on a scale
Malocclusion
Primary: Tooth Movement Between the Groups — 4.345; 4.04 percentage of movement
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 28; 30; 30; 30 Injections
Phenylketonuria
Primary: Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood — 130; 137; 961 umol/L
Diabetes
Primary: Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method — 127 Blood…
Crohn's Disease
Primary: Adverse Event — 37 Subjects
Bronchiolitis
Primary: Duration of Cough — 13; 11 days